Free Trial

Monopar Therapeutics (MNPR) Competitors

Monopar Therapeutics logo
$32.33 +0.49 (+1.54%)
As of 03:27 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

MNPR vs. PGEN, AKBA, AVXL, NRIX, NAGE, PHAR, AVBP, SANA, GYRE, and OCS

Should you be buying Monopar Therapeutics stock or one of its competitors? The main competitors of Monopar Therapeutics include Precigen (PGEN), Akebia Therapeutics (AKBA), Anavex Life Sciences (AVXL), Nurix Therapeutics (NRIX), Niagen Bioscience (NAGE), Pharming Group (PHAR), ArriVent BioPharma (AVBP), Sana Biotechnology (SANA), Gyre Therapeutics (GYRE), and Oculis (OCS). These companies are all part of the "pharmaceutical products" industry.

Monopar Therapeutics vs. Its Competitors

Monopar Therapeutics (NASDAQ:MNPR) and Precigen (NASDAQ:PGEN) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

1.8% of Monopar Therapeutics shares are owned by institutional investors. Comparatively, 33.5% of Precigen shares are owned by institutional investors. 20.5% of Monopar Therapeutics shares are owned by insiders. Comparatively, 47.1% of Precigen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Monopar Therapeutics has a beta of 1.05, suggesting that its share price is 5% more volatile than the S&P 500. Comparatively, Precigen has a beta of 1.87, suggesting that its share price is 87% more volatile than the S&P 500.

Monopar Therapeutics has a net margin of 0.00% compared to Precigen's net margin of -2,868.66%. Monopar Therapeutics' return on equity of -41.76% beat Precigen's return on equity.

Company Net Margins Return on Equity Return on Assets
Monopar TherapeuticsN/A -41.76% -39.49%
Precigen -2,868.66%-842.83%-78.98%

In the previous week, Precigen had 34 more articles in the media than Monopar Therapeutics. MarketBeat recorded 47 mentions for Precigen and 13 mentions for Monopar Therapeutics. Precigen's average media sentiment score of 0.52 beat Monopar Therapeutics' score of 0.45 indicating that Precigen is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Monopar Therapeutics
3 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Precigen
15 Very Positive mention(s)
9 Positive mention(s)
13 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Monopar Therapeutics has higher earnings, but lower revenue than Precigen. Precigen is trading at a lower price-to-earnings ratio than Monopar Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Monopar TherapeuticsN/AN/A-$15.59M-$3.33-9.71
Precigen$3.92M316.59-$126.24M-$0.42-9.92

Monopar Therapeutics presently has a consensus price target of $60.00, indicating a potential upside of 85.59%. Precigen has a consensus price target of $8.25, indicating a potential upside of 98.08%. Given Precigen's higher probable upside, analysts clearly believe Precigen is more favorable than Monopar Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Monopar Therapeutics
0 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.83
Precigen
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.80

Summary

Precigen beats Monopar Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Monopar Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for MNPR and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MNPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MNPR vs. The Competition

MetricMonopar TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$198.61M$3.09B$5.82B$9.75B
Dividend YieldN/A2.23%3.84%4.09%
P/E Ratio-9.6721.0131.1425.96
Price / SalesN/A396.98475.48122.90
Price / CashN/A43.0937.1558.38
Price / Book3.828.069.116.38
Net Income-$15.59M-$54.72M$3.26B$265.56M
7 Day Performance-9.47%2.30%1.94%1.81%
1 Month Performance-28.51%7.21%4.91%1.14%
1 Year Performance1,071.34%12.85%31.21%20.98%

Monopar Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MNPR
Monopar Therapeutics
2.9046 of 5 stars
$32.33
+1.5%
$60.00
+85.6%
+1,134.1%$198.61MN/A-9.6710
PGEN
Precigen
3.9134 of 5 stars
$2.95
+0.3%
$6.00
+103.4%
+205.9%$876.04M$3.92M-7.02190News Coverage
Analyst Forecast
Options Volume
Analyst Revision
AKBA
Akebia Therapeutics
3.8876 of 5 stars
$3.11
-4.3%
$6.75
+117.0%
+114.1%$861.72M$203.73M-18.29430
AVXL
Anavex Life Sciences
3.9212 of 5 stars
$9.59
-3.5%
$44.00
+358.8%
+50.4%$854.21MN/A-16.8240Analyst Forecast
NRIX
Nurix Therapeutics
2.3985 of 5 stars
$10.20
-3.6%
$28.87
+183.0%
-59.6%$808.83M$54.55M-3.91300High Trading Volume
NAGE
Niagen Bioscience
1.3419 of 5 stars
$10.12
+1.0%
$13.42
+32.6%
N/A$799.13M$116.30M48.19120
PHAR
Pharming Group
2.0036 of 5 stars
$12.39
+6.4%
$30.00
+142.1%
+54.8%$798.20M$297.20M-95.31280Gap Up
AVBP
ArriVent BioPharma
2.4707 of 5 stars
$19.24
-1.5%
$39.14
+103.4%
-16.9%$792.31MN/A-4.7940
SANA
Sana Biotechnology
2.9986 of 5 stars
$3.40
+2.1%
$8.00
+135.3%
-32.1%$791.90MN/A-3.21380
GYRE
Gyre Therapeutics
0.1195 of 5 stars
$7.85
-3.6%
N/A-36.9%$783.99M$102.19M785.7940Gap Up
OCS
Oculis
3.2654 of 5 stars
$18.06
+0.9%
$35.33
+95.6%
+49.1%$781.56M$780K-6.842News Coverage
Positive News
Earnings Report
Upcoming Earnings
Analyst Forecast

Related Companies and Tools


This page (NASDAQ:MNPR) was last updated on 8/22/2025 by MarketBeat.com Staff
From Our Partners